Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bremelanotide in Diabetic Kidney Disease
NCT05709444Phase 2Completed
- Sponsor
- Palatin Technologies, Inc.
- Start
- Dec 2022
- Primary completion
- Apr 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bremelanotide in diabetic nephropathy (DN), sponsored by Palatin Technologies, Inc.. Started Dec 2022; status: completed.
02
Drugs
bremelanotide
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT05709444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05709444.